All In Biotech

Drug Trial Radar · NCT01709578

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists

Last checked: Nov 20, 2026Latest source record: Aug 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 546 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

546

Actual

Start

Oct 2012

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Regeneron Pharmaceuticals
First posted
Oct 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: To demonstrate that sarilumab added to disease modifying anti-rheumatic drugs (DMARDs) were effective for: * reduction of signs and symptoms at Week 24 and * improvement of physical function at Week 12 in participants with active rheumatoid arthritis (RA) who were inadequate responders or intolerant to tumor necrosis factor alpha (TNF-α) antagonists. Secondary Objectives: The secondary objectives were to investigate the effects of SAR153191 (REGN88) when added to DMARD therapy, in participants with active RA who were inadequate responders or intolerant to TNF-α antagonists, for: * Reduction of signs and symptoms at Week 12; * Improvement in physical function at Week 24; * Improvement in disease activity score as measured by other American College of Rheumatology (ACR) derived components at Weeks 12 and 24; * Improvement in quality of life as measured by participant reported outcomes (PROs) at intermediate visits and Week 24. To assess the exposure of sarilumab added to DMARD therapy in this population. To assess the safety of sarilumab in this population.

Conditions

  • Rheumatoid Arthritis

Interventions

  • SarilumabDrug

    Pharmaceutical form:solution Route of administration: subcutaneous

  • placeboDrug

    Pharmaceutical form:solution Route of administration: subcutaneous

  • hydroxychloroquineDrug

    Dispensed according to the local practice.

  • methotrexateDrug

    Dispensed according to the local practice.

  • sulfasalazineDrug

    Dispensed according to the local practice.

  • leflunomideDrug

    Dispensed according to the local practice.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved at Least 20% Improvement in the American College of Rheumatology (ACR20) Criteria at Week 24Time frame: Week 24
  2. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12Time frame: Baseline, Week 12

Locations

196 sites in 30 countries. Site status is shown where the registry gives one.

  • Investigational Site Number 840070

    Anniston, Alabama

  • Investigational Site Number 840138

    Birmingham, Alabama

  • Investigational Site Number 840142

    Phoenix, Arizona

  • Investigational Site Number 840134

    Fullerton, California

  • Investigational Site Number 840141

    Glendale, California

  • Investigational Site Number 840111

    La Jolla, California

  • Investigational Site Number 840135

    San Diego, California

  • Investigational Site Number 840021

    Santa Maria, California

  • Investigational Site Number 840100

    Stanford, California

  • Investigational Site Number 840049

    Upland, California

  • Investigational Site Number 840131

    Whittier, California

  • Investigational Site Number 840201

    Denver, Colorado

  • Investigational Site Number 840130

    Lewes, Delaware

  • Investigational Site Number 840125

    DeBary, Florida

  • Investigational Site Number 840048

    Miami, Florida

  • Investigational Site Number 840024

    Naples, Florida

  • Investigational Site Number 840006

    Orlando, Florida

  • Investigational Site Number 840128

    Ormond Beach, Florida

  • Investigational Site Number 840063

    Palm Harbor, Florida

  • Investigational Site Number 840060

    Sarasota, Florida

  • Investigational Site Number 840140

    Tampa, Florida

  • Investigational Site Number 840126

    Vero Beach, Florida

  • Investigational Site Number 840018

    Idaho Falls, Idaho

  • Investigational Site Number 840110

    Meridian, Idaho

  • Investigational Site Number 840052

    Kansas City, Kansas

  • Investigational Site Number 840015

    Lexington, Kentucky

  • Investigational Site Number 840120

    Baton Rouge, Louisiana

  • Investigational Site Number 840109

    Lake Charles, Louisiana

  • Investigational Site Number 840055

    Frederick, Maryland

  • Investigational Site Number 840150

    Lansing, Michigan

  • Investigational Site Number 840137

    Saint Clair Shores, Michigan

  • Investigational Site Number 840037

    Tupelo, Mississippi

  • Investigational Site Number 840112

    Lincoln, Nebraska

  • Investigational Site Number 840106

    Orchard Park, New York

  • Investigational Site Number 840121

    Rochester, New York

  • Investigational Site Number 840115

    Roslyn, New York

  • Investigational Site Number 840118

    Smithtown, New York

  • Investigational Site Number 840139

    Syracuse, New York

  • Investigational Site Number 840123

    Charlotte, North Carolina

  • Investigational Site Number 840116

    Wilmington, North Carolina

Showing 40 of 196 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.